• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Bedside Checklists Could Prevent Most ABO-Incompatible Transfusions and Other Adverse Events

August 16, 2017

Since 1996, the hemovigilance surveillance system in the United Kingdom has collected and published yearly reports on the serious hazards of transfusions (SHOT). In 2016, almost 2.5 million components were transfused in the U.K., including 1.8 million red blood cell (RBC) transfusions.  The number of deaths in the U.K. due to ABO-incompatible transfusions have decreased during the last decade (15 deaths from 1996-2005 compared to 5 deaths from 2006-2016), and only 12.5% of all SHOT reports in 2016 were due to adverse reactions.  Almost all of the SHOT reports filed during 2016 were due to errors (2688/3091, 87%), many of which were preventable. Only 3 ABO-incompatible RBC transfusions occurred, but there were 264 near misses that were caught in the laboratory or at the patient’s bedside.  Furthermore, over half of the deaths (14/26, 53.8%) due to transfusions in 2016 were due to transfusion-associated circulatory overload (TACO). Thus, the key recommendations from the 2016 SHOT Report are use of bedside checklists to prevent incompatible errors and to check for pulmonary complications that may be associated with TACO.

Reference:

PHB Bolton-Maggs (Ed) D Poles et al.  on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2016 Annual Shot Report (2017).

Filed Under

  • Adverse Events (non-infectious)
  • News

Recommended

  • U.S. FDA Advises Blood Community Regarding Monkeypox Virus

  • Systematic Review Recommends Standard Ratios of Blood Products for Massive Transfusion

  • AABB and the CDC Outline Guidelines for Laboratory Testing of Patients with Suspected Ebola

Show Comments

Reader Interactions

Comments

  1. Dr Jose A Garcia Erce says

    August 22, 2017 at 7:24 am

    Over half of the deaths (14/26, 53.8%) due to transfusions in 2016 were due to transfusion-associated circulatory overload (TACO). (Like in 2013)

    TACO is actually the most important and frequent cause of death!
    One unique unit transfusion must be mandatory in non-bleeding hemodinamicaly stable patients! The most often DO NOT DO Recommendation!
    And premedication with diuretics must be study in large RCT!

  2. Aman Dhesi says

    August 22, 2017 at 8:39 am

    Based on the SHOT recommendation, the NHSBT Patient Blood Management Team have produced the bedside checklist in a handy lanyard card. They can be ordered for free – but stocks are limited. Just ask your local Transfusion Practitioner or Patient Blood Management Practitioner.

  3. Emmanuel Benjamin (Med. Lab. Scientist) says

    August 28, 2017 at 7:25 pm

    As Haematologist practising in developing country (Nigeria), this is very useful and it is an eye opener.

  4. Emmanuel Benjamin (Med. Lab. Scientist) says

    August 28, 2017 at 7:28 pm

    very interesting.

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley